6998 — Edding Genor group Share News
0.000.00%
Last trade - 00:00- HK$3.32bn
- HK$3.87bn
- CNY2.49bn
Brief: Jhbp Cy Posts Loss For Year RMB865.4 Mln
Brief: Jhbp Cy Says Infliximab Got Approval From China's Nmpa For Treatment Of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Among Others
Brief: Jhbp Cy Says Guo Feng Appointed As Chairman
Brief: JHBP Cy Posts HY Loss Attributable RMB400.9 Mln Vs Loss Of RMB533.4 Mln
Brief: JHBP CY Received Investigational New Drug Approval For Gb492 By NMPA
Brief: JHBP CY Holdings Posts FY Total Comprehensive Loss RMB3,032.8 Mln
Brief: Jhbp Cy Says NMPA Approves Investigational NDA For Two Gb491 (Lerociclib) Bridging Studies
Brief: JHBP CY Says NMPA Accepts New Drug Application For GB242
Chinese biopharmaceutical group JHBP shines in Hong Kong debut